Valuation: Onconic Therapeutics Inc.

Market Cap 717B 506M 439M 411M 375M 705M 48.3B 716M 4.83B 1.89B 24.18B 1.9B 1.86B 80.64B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 665B 469M 407M 381M 347M 653M 44.76B 663M 4.48B 1.75B 22.41B 1.76B 1.72B 74.72B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.87%
Yield 2024 *
-
Yield 2025 -
1 day+6.40%
1 week+21.26%
Current month+46.03%
1 month+35.04%
3 months-27.36%
6 months-16.84%
Current year-19.18%
1 week 13,660
Extreme 13660
15,840
1 month 8,790
Extreme 8790
16,920
Current year 8,790
Extreme 8790
28,900
1 year 5,662.5
Extreme 5662.499999
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2020
Director of Finance/CFO 50 01/01/2020
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 01/01/2020
Director/Board Member 59 01/01/2020
Director/Board Member 44 26/03/2024
Date Insider Type Main position Quantity % Market Cap.
22/4/25 Fiscal year 50,000 0.4595%
18/4/25 Fiscal year

Chief Technology Officer

12,500 0.1149%
17/4/25 Fiscal year

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
+6.40%+21.26%+154.33% - 477M
-0.73%+7.82%+73.81%+102.34% 70.51B
+1.60%+1.66%+37.76%+67.36% 54.05B
-0.22%+33.59%+8.43%+489.75% 28.95B
+1.27%+10.63%+48.64%+7.59% 24.05B
-0.06%+0.61%-16.45%-13.26% 23.31B
-1.37%+7.87%+251.71%+464.53% 18.67B
+2.21%+7.66%+47.18%-20.09% 18.37B
+0.66%+4.43%+26.79%+626.71% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.72B
Average +0.65%+7.64%+66.50%+206.56% 26.72B
Weighted average by Cap. +0.12%+9.56%+55.25%+168.74%

Financials

2024 2025
Net sales 14.84B 10.47M 9.07M 8.5M 7.75M 14.58M 999M 14.8M 99.99M 39.09M 500M 39.32M 38.47M 1.67B 53.39B 37.68M 32.65M 30.59M 27.9M 52.46M 3.59B 53.26M 360M 141M 1.8B 141M 138M 6B
Net income -8.09B -5.71M -4.95M -4.64M -4.23M -7.95M -545M -8.07M -54.53M -21.32M -273M -21.45M -20.98M -910M 15.78B 11.14M 9.65M 9.04M 8.25M 15.51M 1.06B 15.75M 106M 41.58M 532M 41.83M 40.92M 1.77B
Net Debt -42.69B -30.13M -26.11M -24.46M -22.31M -41.94M -2.87B -42.59M -288M -112M -1.44B -113M -111M -4.8B -52.61B -37.13M -32.17M -30.14M -27.49M -51.69M -3.54B -52.48M -355M -139M -1.77B -139M -136M -5.91B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
12/08/26 KRW 15,800.00 +6.40% 1,587,978
11/08/26 KRW 14,850.00 +1.23% 537,442
10/08/26 KRW 14,670.00 +4.41% 486,932
07/08/26 KRW 14,050.00 -11.86% 901,974
06/08/26 KRW 15,940.00 +22.33% 4,611,291
  1. Stock Market
  2. Stocks
  3. A476060 Stock